Vaxxinity, Inc. (NASDAQ:VAXX – Get Rating) saw a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 392,800 shares, a growth of 44.9% from the April 15th total of 271,000 shares. Based on an average trading volume of 787,900 shares, the short-interest ratio is presently 0.5 days. Approximately 1.1% of the company’s stock are sold short.
Several research firms have weighed in on VAXX. Evercore ISI began coverage on shares of Vaxxinity in a report on Wednesday, April 27th. They set an “in-line” rating on the stock. Zacks Investment Research upgraded shares of Vaxxinity from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Saturday.
Shares of VAXX stock opened at $4.37 on Friday. The firm has a 50-day moving average price of $4.29. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.46 and a quick ratio of 5.61. Vaxxinity has a one year low of $3.04 and a one year high of $22.77.
Vaxxinity (NASDAQ:VAXX – Get Rating) last announced its earnings results on Thursday, March 24th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.13). On average, equities research analysts anticipate that Vaxxinity will post -1.38 earnings per share for the current fiscal year.
In other Vaxxinity news, insider Mei Mei Hu acquired 8,038 shares of the stock in a transaction on Monday, April 25th. The shares were purchased at an average price of $3.37 per share, for a total transaction of $27,088.06. Following the completion of the acquisition, the insider now owns 51,593,454 shares in the company, valued at approximately $173,869,939.98. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder United Biomedical Inc acquired 18,105 shares of the stock in a transaction on Tuesday, April 26th. The shares were acquired at an average price of $3.45 per share, for a total transaction of $62,462.25. Following the acquisition, the insider now owns 51,611,559 shares of the company’s stock, valued at approximately $178,059,878.55. The disclosure for this purchase can be found here. Insiders have purchased a total of 30,950 shares of company stock worth $106,759 in the last quarter.
Several hedge funds have recently made changes to their positions in VAXX. FNY Investment Advisers LLC bought a new position in Vaxxinity during the fourth quarter valued at about $27,000. Virtu Financial LLC purchased a new stake in Vaxxinity during the fourth quarter worth about $93,000. ETF Managers Group LLC purchased a new stake in Vaxxinity during the fourth quarter worth about $211,000. Geode Capital Management LLC purchased a new stake in Vaxxinity during the fourth quarter worth about $382,000. Finally, Millennium Management LLC purchased a new stake in Vaxxinity during the fourth quarter worth about $489,000. Institutional investors own 15.82% of the company’s stock.
Vaxxinity Company Profile (Get Rating)
Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer’s disease; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson’s disease and other synucleinopathies, such as dementia with Lewy Body and multiple system atrophy; and an anti-tau product candidate for various neurodegenerative conditions, including AD.